[1] Arendrup MC.Epidemiology of invasive candidiasis[J].Curr Opin Crit Care,2010,16(5):445-452.
[2] Katiyar SK,Alastruey-Izquierdo A,Healey KR,et al.Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata:implications for echinocandin resistance[J].Antimicrobial and chemotherapy,2012,12(56):6304-6309.
[3] Alexander BD,Johnson MD,Pfeiffer CD,et al.Increasing echinocandin resistance in Candida glabrata:clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations[J].Clinical Infectious Disease,2013,56(12):1724-1732.
[4] Castanheira M,Woosley LN,Pfaller MA,et al.Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida spp[J].Antimicrobial and chemotherapy,2010.,54(6):2655-2659.
[5] Walker LA,Gow NA,Munro CA.Fungal echinocandin resistance[J].Fungal Genet Biol,2010,47(2):117-126.
[6] Cowen LE.The evolution of fungal drug resistance:modulating the trajectory from genotype to phenotype[J].Nat Rev Microbiol,2008,6(3):187-198.
[7] Park,S,R.Kelly,N.Kahn,et al.Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp Isolates[J].Antimicrob Agents Chemother,2005,49(8):3264-3273.
[8] Garcia-Effron,G,S.Lee,S.Park,et al.Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3- -D-glucan synthase:implication for the existing susceptibility breakpoint[J].Antimicrob Agents Chemother,2009,53(9):3690-3699.
[9] Nicholas D.Beyda,Julie John,Abdullah Kilic,et al.FKS mutant Candida glabrata;risk factors and outcomes in patients with candidemia[J].Clinical Infectious Diseases,2014,59(6):819-825.
[10] Mariana Castanheira,Leah N.Woosley,et al.Frequency of fks Mutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates[J].Antimicrob Agents Chemother,2014,58(1):577.
[11] Zimbeck AJ,Iqbal N,Ahlquist AM,et al.FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S.population-based surveillance[J].Antimicrob Agents Chemother,2010,54(12):5042-5047.
[12] Pham CD,Iqbal N,Bolden CB,et al.The role of FKS mutations in C.glabrata:MIC values,echinocandin resistance and multidrug resistance[J].Antimicrob Agents Chemother,2014 58(8):4690-4696.
[13] Sheen a D.Singh-Babak,Tomas Babak,Stephanie Diezmann,et al.Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata[J].PLOS Pathogens,2012,8(5):1-23.
[14] Lepak A,Castanheira M,Diekema D,et al.Optimizing echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations[J].Antimicrob Agents Chemother,2012,56(11):5875-5882.
[15] Fabiola Fernandez-Silva,Michaela Lackner,Javier Capilla,et al.In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection[J].Antimicrob.Agents Chemother,2014,58(7):3646-3649.
[16] Arendrup MC,Perlin DS,Jensen RH,et al.Differential in vivo activities of anidulafungin,caspofungin,and micafungin against 458 Candida glabrata isolates with and without FKS resistance mutations[J].Antimicrob.Agents Chemother,2012,56(5):2435-2442.
[17] Andes D,Diekema DJ,JPfaller MA,et al.In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species[J].Antimicrob Agents Chemother,2010,54(6):2497-2506.
[18] Pappas PG,et al.Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis[J].Clin.Infect Dis,2007,45(7):883- 893.
[19] Shields RK,Nguyen MH,Press EG,et al.2012.The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.Antimicrob[J].Agents Chemother,2012,56(9):4862-4869.
[20] Pfeiffer CD,Garcia-Effron G,Zaas AK,et al.Breakthrough invasive candidiasis in patients on micafungin[J].Clin Microbiol,2010,48(7):2373-2380.
[21] Kyoko Niimi,Matthew A.Wood,Katsuyuki maki,et al.Reconstitution of high-level micafungin resistance detected in a clinical isolate of Candida glabrata identifies functional homozygosity in glucan synthase gene expression[J].Antimicrob Chemother,2012,67(7):1666 -1676. |
